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bstract
Ochratoxin A (OTA) produced by Aspergillus and Penicillium genera contaminates several foods. OTA is nephrotoxic to all animal species
tudied so far, and most likely to humans, who show the longest half-life for elimination of this toxin among all examined species. OTA has other
oxic effects such as teratogenicity, immunotoxiity, genotoxicity, and is also mutagenic and carcinogenic, all of which lead to life-threatening
athologies through several molecular pathways.
A sensitive, specific and rapid method applying high performance liquid chromatography coupled to a spectrofluorimeter for the determination
f ochratoxin A in human serum was validated. Serum samples were extracted with chloroform–orthophospohric acid, and cleaned-up through
mmunoaffinity column (IAC). The separation and identification was performed by HPLC coupled to a spectrofluorimeter, and, after OTA methy-
ation, the confirmation was achieved. Chromatographic separation of the analyte was performed on a reverse phase column with a mobile phase
f water:acetonitrile:glacial acetic acid (49.5:49.5:1.0). Linearity was established between the range of 1 and 10 ng/ml. Under the optimized con-
itions, the recoveries were higher than 83.0% for all fortification levels. The intra-day precision oscillated between 8.0 and 5.0% at levels of 0.25
nd 0.5g/l, while the inter-day precision was in the range of 10.7–16.0%. The limit of quantification of the method was 0.05g/l. The method
s appropriate for quantitative determination of OTA in human serum and has been successfully applied to the analysis of OTA in haemodialysis
atients from two principal cities of Portugal, in order to evaluate its exposure degree.
Levels of OTA in Coimbra were higher than in Aveiro, 0.50g/l versus 0.49g/l. In respect to gender, levels of OTA were higher in males
rom Aveiro than in females, 0.52g/l versus 0.44g/l, and in Coimbra were similar, 0.50g/l versus 0.51g/l. However, in none of the cases,
ignificant statistical differences were found.
2006 Elsevier B.V. All rights reserved.
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. Introduction
Ochratoxin A (OTA) is a mycotoxin produced by several
spergillus and Penicillium species. Among Aspergillus species
here are two in section Nigri and four in section Circumdati,
ormerly the Aspergillus ochraceus group, now referred to as
spergillus alutaceus [1–3]. The presence of OTA in human
lood or serum is related with contaminated food ingestion.
enicillium verrucosum and Aspergillus species have been con-
istently associated with cereals and coffee beans, respectively.
spergillus niger and carbonarius have been isolated from dried
ine fruit [1,4]. Other food items, such as milk [5], animal tis-
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ues, muscle, organs, and eggs [2,3,6], pulses, wine and beer
1,7–9] have also been contaminated.
Recognized as carcinogenic, teratogenic, immunotoxic,
enotoxic, as well nephrotoxic [1–3,9], the evaluation of OTA
evels in different type of populations is unquestionable to pro-
ide data about exposure and evaluate the possible human health
isk of OTA.
Only few studies carried out in Europe [10–12], and Africa
13–16] reported the possible connection between the presence
f OTA in human serum and nephropathy. Investigations in dif-
erent countries have shown that OTA occurs in nephropathy
atients with different mean concentrations in blood. These lev-
ls oscillated between 0.34g/l, in Egypt [15] and 85.3g/l, in
unisia [17].
The aim of this work was validate one hyphenated tech-
ique using HPLC coupled to a spectrofluorimeter for the
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2.5. Confirmation
Sample extracts were evaporated to dryness under N2 stream,
150l BF3 (14% methanolic solution) were added, and the
Table 1
Data for accuracy and intra- and inter-assay validation (n = 3)
Fortification Recovery RSD intra-day RSD inter-day54 A.M.P. Dinis et al. / Journal of Pharmaceuti
etermination of OTA levels in serum, and to evaluate, at the first
ime, the exposure of two populations undergoing haemodialy-
is from the central zone of Portugal, Coimbra and Aveiro. Mean
oncentrations of OTA in both genders were also studied in the
wo analysed populations. The OTA identity was confirmed by
ethyl ester formation.
. Experimental
.1. Sampling and description of populations
The study was carried out in 2003 in the two most important
ities of the central region of Portugal, Coimbra and Aveiro, far
rom each one another 60 km. OTA serum levels were evaluated
n 95 donors undergoing haemodialysis, 50 from Coimbra (27
ens and 23 womens) and 45 from Aveiro (26 mens and 19 wom-
ns). Blood samples were collected in November/December
002 and September 2003 in Coimbra and Aveiro, respectively.
he donors enrolled in this study were all volunteers, clearly
nformed and fully consenting.
In Coimbra and Aveiro the mean donor age was 66 ± 14, and
6 ± 15, respectively, while the mean weights were 66 ± 13 and
5 ± 13.
Blood samples were collected in glass tubes (50 ml), and
he serum samples were obtained by heating the tubes at 37 ◦C
or 3 h, and submitting them to centrifugation at 1510 × g for
0 min.
.2. Reagents
HPLC grade acetonitrile, chloroform, toluene, and methanol
ere purchased from Carlo Erba (Milan, Italy). Acetic acid,
ydrochloride acid, sodium hydroxide, potassium chloride,
otassium dihydrogenphosphate, anhydrous disodium hydro-
enphosphate, sodium hydrogencarbonate, sodium chloride,
nd 85% orthophosphoric acid were obtained from Merck
Darmstadt, Germany). Water was purified by distillation and
assage through a Milli-Q system (Millipore, Bedford, MA,
SA). OTA with purity grade ≥98%, and a boron trifluoride
4% methanolic solution were purchased from Sigma Chemical
o. (St. Louis, MO, USA).
Imunoaffinity columns OchratestTM IAC were from VICAM
Watertown, USA).
.3. Preparation of stock and standards solutions
A standard solution of OTA was prepared from the OTA
ial purchased from Sigma. The standard stock solution was
ade in 4 ml toluene:acetic acid (99:1) at 250g/ml, and stored
t −20 ◦C. An intermediate standard solution was prepared at
0g/ml, by diluting 1 ml of stock standard solution with 25 ml
oluene:acetic acid (99:1). For fortification assays, a standard
olution was prepared in toluene:acetic acid (99:1) at 1g/ml.For the calibration curve, standard solutions were prepared
y evaporating 10l of stock solution to dryness, and dilut-
ng to 10 ml with mobile phase. After suitable dilutions in
ater:methanol:acetic acid (49.5:49.5:1), the working standard
l
0
0
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olution was used to prepare the external calibration curve (1, 2,
, and 10 ng/ml).
.4. Analysis of ochratoxin A
.4.1. Extraction and clean-up
Two milliliter of serum added with 10 ml of a solution con-
aining 33.7 ml of 85% orthophosphoric acid and 118 g sodium
hloride per liter, were vortex mixed for 1 min. Afterwards, 2×
ml of chloroform were added, and after an intensive vortex
ixing for 3 min it was centrifuged at 2485 × g for 15 min.
he organic phase was evaporated to dryness at 30–40 ◦C. The
ry extract was dissolved in 5 ml of PBS–methanol and passed
hrough IAC column. This procedure was repeated three times.
fter passage of the solution, the column was washed with water
nd dried by air. OTA was then eluted with 3 ml methanol, and
vaporated to dryness at 30–40 ◦C under a gentle steam of N2.
he concentrated residue was dissolved in 250l of mobile
hase and injected in the HPLC system.
.4.2. Detection and quantification
For detection an HPLC system consisting of a pump, model
07 (Gilson, France), one 20l injection valve, model 7125
Rheodyne, Cotati, California, USA), a guard column, C18
.5m Nucleosil 120 KS (30 mm × 4 mm i.d.), and a column,
18 5m Nucleosil 100 (250 mm × 4.6 mm i.d.) was used. A
pectrofluorimeter, model LS-45 (Perkin-Elmer, USA) was cou-
led to the HPLC, and the analyses were made using 333 nm for
xcitation and 460 nm for emission. An integrator, model 3390A
Hewlett-Packard), was used to measure peak areas.
The mobile phase consisted of a mixture of water:
cetonitrile:glacial acetic acid (49.5:49.5:1.0) at a flow rate of
ml/min.
.4.3. Validation studies
Linearity was evaluated in the range of 0.02–0.2 ng
1–10 ng/ml).
The recovery studies were made by adding OTA standard
olution, prepared in toluene:acetic acid (99:1), to three repli-
ates of serum. For these studies, 0.5, 1.0 and 2.0 ng of OTA,
quivalent to fortification levels of 0.25, 0.5 and 1.0 ng/ml,
espectively, were added to 2 ml serum, and allowed to stand
or 15 min at room temperature before extraction (Table 1).evel (g/l) mean (%) (%) (%)
.25 83 8.0 10.7
.5 114 5.0 12.0
.0 86 5.3 16.0
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respectively [10–12,16].
Levels of OTA in women and in men from Coimbra are sim-
ilar, 0.51 ± 0.28g/l versus 0.50 ± 0.32g/l, with P = 0.793.
In Aveiro, the OTA mean concentrations in men were higher,
Table 2
Minimum, maximum, mean concentration, S.D., and median of OTA (g/l) in
patients undergoing hemodialysis of two cities in central zone of Portugal
Coimbra Aveiro
Minimum 0.12 0.15A.M.P. Dinis et al. / Journal of Pharmaceuti
ixture was left at 60 ◦C for 10 min. After evaporation under
2, the residue was dissolved in 150l water:acetonitrile:glacial
cetic acid (49.5:49.5:1.0). The OTA methyl esters were anal-
sed according to the HPLC method described above.
.6. Statistical analysis
Database management and statistical analysis were per-
ormed with the SPSS 10.0 Microsoft version. The differences
n the OTA levels between different populations were tested with
he Kruskal–Wallis test. P≤ 0.05 (two-tailed) was considered to
e statistically significant.
. Results and discussion
The calibration curve was obtained using the linear least-
quares regression procedure of the peak area versus the
oncentration. OTA linearity, in the working standard solutions
t three determinations of four concentration levels, between 1
nd 10 ng/ml, namely 1, 2, 5, and 10 ng/ml, was good as shown
y the fact that the correlation coefficient (r2) was 0.9998.
In respect to the extraction procedure, good results were
chieved by the use of chloroform, after addition of orthophos-
horic acid and sodium chloride, similarly to the extraction
chratoxin A in muscle [6]. For serum samples, best accu-
acy results were obtained when sodium hydrogen carbonate
olution was substituted by sodium chloride. More labori-
us and complex extraction procedures are usually reported.
hese methods generally involve dilution with magnesium
hloride and chloridric acid and extraction with chloroform
1,10,14,15]. Some of them involve even more complexity,
ecause the residue is suspended in methanol following dilution
ith Tris/chloridric or sulphuric acid buffer at pH 7.5, before
he clean-up procedure [1,14]. Depending on the extracts, some
leanup procedures have been tried, but, owing to its specificity,
he use of immunoaffinity columns (IAC) for serum or plasma
as been documented [14,16]. Solid-phase extraction with C18
dsorbent [13,17,18] and liquid partition with sodium hydrogen
arbonate have been also used [15]. Detection and quantification
re usually made by liquid chromatography with fluorescence
etection [1,13,17,18].
The HPLC method proposed, previously developed in our
atest studies [4,6,19,20] exhibits good analytical performance
or OTA analysis. For fluorescence detection, a spectrum of
TA standard solution in HPLC mobile phase was obtained in
rder to optimize OTA detection. The maximum emission wave-
ength at an excitation wavelength of 333 nm, was found to be at
60 nm.
Comparing to other published methods involving the use of
ore complex mobile phases with ionic pair reagents and buffers
1,13,15–18], a simple mobile phase, consisting of a mixture of
ater:acetonitrile:glacial acetic acid (49.5:49.5:1.0) was used.
Accuracy and precision of the analytical methodology for allhe fortification levels were adequate and in accordance to inter-
ational parameters [21–23] (Table 1). Recovery values varied
etween 83 and 114%, at levels of 0.25 and 0.5g/l, respec-
ively. The intra-day precision oscillated between 8.0 and 5.0%
M
M
S
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t levels of 0.25 and 0.5g/l, while the inter-day precision was
n the range of 10.7 and 16.0%.
The limit of quantification was 0.05g/l. According to an
nvestigation on the LOQ obtained values from different meth-
ds used for OTA determination in blood, the results obtained
erein are of the same order as those reported by Thuvander [1],
re better than those reported by Jimenez et al. [10], 0.52g/l,
assen et al. [18], and by Grosso et al. [14], 0.1g/l.
Fig. 1 shows representative liquid chromatography-
pectrofluorimetric chromatograms obtained from an OTA
tandard solution, from one fortified sample serum, and from
ne positive sample.
This study revealed that the frequency of detection in both
roups of donors was 100%. However, studies in Tunisia show
ifferent occurrences, 20.5% [16], between 78 and 100% [18],
etween 87 and 100% [13], and 100% [14], probably due to
ifferent limits of quantification of the analytical methodology
sed [14].
The overall concentrations in nephropathy patients from
oimbra ranged from 0.12 to 1.52g/l, being the mean concen-
ration and standard deviation 0.50 ± 0.29g/l, and the median
.45g/l. Comparing these values with those from Aveiro
opulation, the overall concentrations were between 0.15 and
.03g/l, the mean concentration and standard deviation were
.49 ± 0.22g/l, and the median was 0.42g/l (Table 2). Sig-
ificant differences were not found between OTA levels in the
wo cities (P-value = 0.743).
Comparing these results with those obtained in other coun-
ries, the levels found in nephropathy donors are similar to those
ound in some groups of patients in Egypt with end stage renal
isease (ESRD), 0.47 ± 1.6 2g/l in renal transplant recipients
nd 0.52 ± 1.46g/l in patients with urothelial tumours, and are
igher than 0.34 ± 0.69g/l, found in patients with ESRD under
ialytic therapy. Higher values were detected in patients with
SRD under conservative medical treatment (1.01 ± 1.56g/l)
nd in patients with nephrotic syndrome (2.19 ± 3.07g/l). The
ighest value found in patients undergoing haemodialysis in
oimbra and in Egypt was 1.51 and 2.17g/l, respectively
15]. However, in Navarra-Spain, Bari-Southern Italy, Isparta-
urkey, and Abidjan-Tunisia, highest mean concentrations were
etected in nephropathy patients under dialytic treatment with
.97, 1.4, 2.1, and 1.05g/l, respectively, with maximum val-
es of 11.70, 5.4, and 2.42g/l for Spain, Turkey, and Tunisia,aximum 1.52 1.03
ean 0.50 0.49
tandard deviation 0.29 0.22
edian 0.45 0.42
556 A.M.P. Dinis et al. / Journal of Pharmaceutical and Biomedical Analysis 44 (2007) 553–557
Fig. 1. Liquid chromatography-spectrofluorimetric chromatograms of ochra-
toxin A (OTA) standard (a) (0.25 ng) (retention time 10.90 min), one serum
sample fortified at 0.25g/l (b), and one sample containing 0.98g/l (c).
Table 3
Mean concentration (g/l), S.D., and median of OTA in women (W) and men
(M) serum in the two cities
Coimbra-W Aveiro-W Coimbra-M Aveiro-M
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cean 0.51 0.44 0.50 0.52
tandard deviation 0.28 0.18 0.32 0.24
edian 0.48 0.39 0.41 0.41
.52 ± 0.24g/l, than those found for women, 0.44 ± 0.18g/l.
owever, no significant difference was found, P = 0.265. The
edian was 0.48 and 0.41g/l, for women and men from Coim-
ra, and 0.39 and 0.41g/l for women and men from Aveiro,
espectively (Table 3).
These occurrences may be due to different situations. One
s the highest moisture grade of the different areas, and another
s the probable ingestion of foods with deficient procedures of
onservation. The highest consumption of alcoholic beverages,
ifferent consumption habits, and regional food intake patterns
ay also contribute to these differences. The climate may also
e responsible for fluctuations in human exposure, because the
onsumed food may be contaminated at different levels under
ifferent climatic conditions [10].
In this study, the OTA mean concentration of dialysed
atients, from Coimbra, was similar to that found in a pre-
ious study in healthy donors [24], 0.50 ± 0.29g/l versus
.41 ± 0.17g/l (P = 0.222), suggesting that OTA dialyses out
f plasma into dialysis solution. This may indicate that patients
ndergoing hemodialysis have been exposed to contaminated
oods before sampling, or have been frequently exposed because
f restricted diet in relation to their nephropathy, or that normal
limination via the kidney into urine of glucuronidated metabo-
ites is blocked. These reasons may be involved all together [16].
lood concentrations of OTA in dialysed patients, in Abidjan-
unisia, were lower than OTA in healthy blood donors [16],
robably because the dialysis reduces OTA concentration in
lood of nephropathy patients as previously found by Wafa et
l. [15] in Egypt.
In two studied populations, the estimated daily ingestion
EDI), based in the equation of Breitholtz et al. [25], was
.67 ng/kg b.w. per day in Coimbra (range 0.16–2.04 ng/kg
.w. per day), and 0.65 ng/kg b.w. per day in Aveiro (range
.20–1.38 ng/kg b.w. per day). These results indicate one
ean tolerable daily intake within 0.2–4.2 ng/kg b.w. per day,
stablished by Kuiper–Goodman and Scott in 1989 [2], and
elow 5 ng/kg b.w., the tolerable daily intake (TDI) estimated
y the Scientific Committee on Foods (SFC) of the European
nion in 2002 [26]. These values are in agreement with the data
f the estimated daily intake obtained by the contribution of
oodstuffs in the Portugal central zone, 0.018 ng kg−1 b. w. for
uscle [6], 2.6 ng kg b. w. per day for rice [4], and 0.07 ng/kg
.w. for maize bred [27].
. ConclusionsLevels of OTA in both studied populations are lower than to
atients undergoing hemodialysis from other studied European
ountries.
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